Penalty weight tuning in high dose rate brachytherapy using multi-objective Bayesian optimization
Phys Med Biol. 2024 Apr 26. doi: 10.1088/1361-6560/ad4448. Online ahead of print.ABSTRACTTreatment plan optimization in high dose rate (HDR) brachytherapy often requires manual fine-tuning of penalty weights for each objective, which can be time-consuming and dependent on the planner's experience. To automate this process, this study used a multi-criteria approach called multi-objective Bayesian optimization with q-noisy expected hypervolume improvement as its acquisition function (MOBO-qNEHVI).

Approach: The treatment plans of 13 prostate cancer patients were retrospectively imported to a research treatme...
Source: Physics in Medicine and Biology - April 26, 2024 Category: Physics Authors: Hossein Jafarzadeh Majd Antaki Ximeng Mao Marie Duclos Farhad Maleki Shirin A Enger Source Type: research
Treatment Response Imaging in Prostate Cancer
This study will review the different criteria for imaging treatment response on conventional and advanced molecular imaging for different therapies, and the future perspective in posttherapy imaging.PMID:38670877 | DOI:10.1016/j.cpet.2024.03.009 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Mina Swiha Andrei Gafita Andrew Nguyen Louise Emmett Source Type: research
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data
In this study, we have thoroughly completed a narrative review of the current literature and summarized preclinical studies and clinical trials that evaluated the utility, activity, and toxicity of ADCs in GU cancers, the prospects of ADC development, and the ongoing clinical trials. Prospective clinical trials, retrospective studies, case reports, and scoping reviews were included.PMID:38668075 | PMC:PMC11049516 | DOI:10.3390/curroncol31040172 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Prathana Nathan Adnan Rajeh Meh Noor Gabriel Boldt Ricardo Fernandes Source Type: research
Penalty weight tuning in high dose rate brachytherapy using multi-objective Bayesian optimization
Phys Med Biol. 2024 Apr 26. doi: 10.1088/1361-6560/ad4448. Online ahead of print.ABSTRACTTreatment plan optimization in high dose rate (HDR) brachytherapy often requires manual fine-tuning of penalty weights for each objective, which can be time-consuming and dependent on the planner's experience. To automate this process, this study used a multi-criteria approach called multi-objective Bayesian optimization with q-noisy expected hypervolume improvement as its acquisition function (MOBO-qNEHVI).

Approach: The treatment plans of 13 prostate cancer patients were retrospectively imported to a research treatme...
Source: Physics in Medicine and Biology - April 26, 2024 Category: Physics Authors: Hossein Jafarzadeh Majd Antaki Ximeng Mao Marie Duclos Farhad Maleki Shirin A Enger Source Type: research
1,2,3-Triazole-totarol conjugates as potent PIP5K1 α lipid kinase inhibitors
Bioorg Med Chem. 2024 Apr 23;105:117727. doi: 10.1016/j.bmc.2024.117727. Online ahead of print.ABSTRACTThe human phosphatidylinositol 4-phosphate 5-kinase type I α (hPIP5K1α) plays a key role in the development of prostate cancer. In this work, seventeen derivatives of the natural diterpene totarol were prepared by copper(I)-catalysed Huisgen 1,3-dipolar cycloaddition reaction of the correspondingO-propargylated totarol with aryl or alkyl azides and screened for their inhibitory activities toward hPIP5K1α. Five compounds, 3a, 3e, 3f, 3i, and 3r, strongly inhibited the enzyme activity with IC50 values of 1.44, 0.46, 1.02...
Source: Bioorganic and Medicinal Chemistry - April 26, 2024 Category: Chemistry Authors: Samer Haidar Ángel Amesty Sandra Oramas-Royo Claudia G ötz Ehab El-Awaad Jana Kaiser Sarah B ödecker Amelie Arnold Dagmar Aichele Juan M Amaro-Luis Ana Est évez-Braun Joachim Jose Source Type: research
Image guided radiotherapy in curative treatment for prostate cancer. 5-year results from a randomized controlled trial (RIC-trial)
CONCLUSIONS: Our results support that both 2-D weekly and 3-D daily image guided radiotherapy are safe and efficient treatments for PC and emphasize the need to evaluate technological progress in clinical trials with long follow-up.PMID:38670265 | DOI:10.1016/j.radonc.2024.110309 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - April 26, 2024 Category: Radiology Authors: Jo- Åsmund Lund Stian Lydersen Bj ørg Aksnessæther Arne Solberg Anne Wander ås Christoffer Lerv åg Stein Kaasa Hanne T øndel Source Type: research
Treatment Response Imaging in Prostate Cancer
This study will review the different criteria for imaging treatment response on conventional and advanced molecular imaging for different therapies, and the future perspective in posttherapy imaging.PMID:38670877 | DOI:10.1016/j.cpet.2024.03.009 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Mina Swiha Andrei Gafita Andrew Nguyen Louise Emmett Source Type: research
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data
In this study, we have thoroughly completed a narrative review of the current literature and summarized preclinical studies and clinical trials that evaluated the utility, activity, and toxicity of ADCs in GU cancers, the prospects of ADC development, and the ongoing clinical trials. Prospective clinical trials, retrospective studies, case reports, and scoping reviews were included.PMID:38668075 | PMC:PMC11049516 | DOI:10.3390/curroncol31040172 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Prathana Nathan Adnan Rajeh Meh Noor Gabriel Boldt Ricardo Fernandes Source Type: research
Penalty weight tuning in high dose rate brachytherapy using multi-objective Bayesian optimization
Phys Med Biol. 2024 Apr 26. doi: 10.1088/1361-6560/ad4448. Online ahead of print.ABSTRACTTreatment plan optimization in high dose rate (HDR) brachytherapy often requires manual fine-tuning of penalty weights for each objective, which can be time-consuming and dependent on the planner's experience. To automate this process, this study used a multi-criteria approach called multi-objective Bayesian optimization with q-noisy expected hypervolume improvement as its acquisition function (MOBO-qNEHVI).

Approach: The treatment plans of 13 prostate cancer patients were retrospectively imported to a research treatme...
Source: Physics in Medicine and Biology - April 26, 2024 Category: Physics Authors: Hossein Jafarzadeh Majd Antaki Ximeng Mao Marie Duclos Farhad Maleki Shirin A Enger Source Type: research
1,2,3-Triazole-totarol conjugates as potent PIP5K1 α lipid kinase inhibitors
Bioorg Med Chem. 2024 Apr 23;105:117727. doi: 10.1016/j.bmc.2024.117727. Online ahead of print.ABSTRACTThe human phosphatidylinositol 4-phosphate 5-kinase type I α (hPIP5K1α) plays a key role in the development of prostate cancer. In this work, seventeen derivatives of the natural diterpene totarol were prepared by copper(I)-catalysed Huisgen 1,3-dipolar cycloaddition reaction of the correspondingO-propargylated totarol with aryl or alkyl azides and screened for their inhibitory activities toward hPIP5K1α. Five compounds, 3a, 3e, 3f, 3i, and 3r, strongly inhibited the enzyme activity with IC50 values of 1.44, 0.46, 1.02...
Source: Bioorganic and Medicinal Chemistry - April 26, 2024 Category: Chemistry Authors: Samer Haidar Ángel Amesty Sandra Oramas-Royo Claudia G ötz Ehab El-Awaad Jana Kaiser Sarah B ödecker Amelie Arnold Dagmar Aichele Juan M Amaro-Luis Ana Est évez-Braun Joachim Jose Source Type: research
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data
In this study, we have thoroughly completed a narrative review of the current literature and summarized preclinical studies and clinical trials that evaluated the utility, activity, and toxicity of ADCs in GU cancers, the prospects of ADC development, and the ongoing clinical trials. Prospective clinical trials, retrospective studies, case reports, and scoping reviews were included.PMID:38668075 | DOI:10.3390/curroncol31040172 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Prathana Nathan Adnan Rajeh Meh Noor Gabriel Boldt Ricardo Fernandes Source Type: research
Biodistribution and radiation dosimetry of [99mTc]Tc-N4-BTG in patients with biochemical recurrence of prostate cancer
Conclusion[99mTc]Tc-N4-BTG appears to be a safe diagnostic agent. Compared to GRPR-targeted PET tracers, this99mTc-labelled SPECT agent could contribute to a broader application and better availability of this novel approach. Further research to assess its clinical value is warranted. (Source: EJNMMI Research)
Source: EJNMMI Research - April 26, 2024 Category: Radiology Source Type: research
From biology to the clinic — exploring liver metastasis in prostate cancer
Nature Reviews Urology, Published online: 26 April 2024; doi:10.1038/s41585-024-00875-xIn this Review, the authors provide a comprehensive overview of the epidemiological characteristics, prognosis, biological mechanisms, detection methods and treatment options for liver metastasis in prostate cancer. Guidance for future research directions in the field is also provided. (Source: Nature Reviews Urology)
Source: Nature Reviews Urology - April 26, 2024 Category: Urology & Nephrology Authors: Xudong Ni Yu Wei Xiaomeng Li Jian Pan Bangwei Fang Tingwei Zhang Ying Lu Dingwei Ye Yao Zhu Source Type: research
Impact of preoperative LUTS on Health-Related Quality of Life following Radical Prostatectomy – A propensity score matched longitudinal study
To assess the impact of preoperative lower urinary tract symptoms (LUTS) on long-term health-related quality of life (HRQOL) up to 10 years after radical prostatectomy (RP) for prostate cancer (PC). (Source: Urology)
Source: Urology - April 26, 2024 Category: Urology & Nephrology Authors: Thilo Westhofen, Enya Feyerabend, Alexander Buchner, Boris Schlenker, Armin Becker, Lennert Eismann, Severin Rodler, Friedrich Jokisch, Christian G. Stief, Alexander Kretschmer Source Type: research
Prevalence and determinants of shared decision-making for PSA testing in the United States
Prostate Cancer and Prostatic Diseases, Published online: 26 April 2024; doi:10.1038/s41391-024-00843-xPrevalence and determinants of shared decision-making for PSA testing in the United States (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - April 26, 2024 Category: Urology & Nephrology Authors: Naeem Bhojani Larry E. Miller Kevin C. Zorn Bilal Chughtai Dean S. Elterman Samir Bhattacharyya Ben H. Chew Source Type: research
